Precision Announces Dosing of First Patient
Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome editing platform, announced today it has dosed the first patient in the Phase 1/2a clinical trial of PBCAR0191,…
AskBio Partners with TPG and Vida Ventures
Leading gene therapy company announces $235 million investment to accelerate growth. Asklepios BioPharmaceutical, Inc (AskBio), a developer and manufacturer of Adeno-Associated Virus (AAV) gene therapy therapeutics for underserved patient populations with rare and generally untreatable…
PhaseBio Receives FDA Breakthrough Therapy Designation
PhaseBio Pharmaceuticals, based in Malvern, Penn. and San Diego, announced that its antiplatelet drug PB2452 had received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). PB2452 is a novel, recombinant, human monoclonal antibody antigen-binding fragment…
Honor Recognizes Humacyte’s Progress in Producing Vascular Conduits
Humacyte, an innovator in biotechnology and regenerative medicine, received the Medical Technology Enterprise Consortium (MTEC) Large Project Prototype of the Year Award, in recognition of the development of its human acellular vessel (HAV). The MTEC…
Precision BioSciences Announces Closing of IPO
Duke start-up, Precision BioSciences, has closed its initial public offering of 9,085,000 shares of common stock at a public offering price of $16.00 per share, for total gross proceeds of approximately $145.4 million. This includes…
Humacyte Turns Acellular Vessels into Living Blood Vessels
Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation” RESEARCH TRIANGLE PARK, N.C. –March 27, 2019 – Humacyte is an innovator in biotechnology and…
PhaseBio Reports Full Results from Phase 1 Clinical Trial
PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) announced today that results from their Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet…
PhaseBio Reports Full Results from Phase 1 Clinical Trial
PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) announced today that results from their Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet…
Precision Biosciences hoping to raise $100 million through an IPO
DURHAM A biotechnology company based in downtown Durham has filed plans to go public — a move that could net the company around $100 million. Precision BioSciences, which has offices at the historic Venable Center…